SINGAPORE, Jan. 5, 2026 /PRNewswire/ -- North London Collegiate School (Singapore) proudly celebrates a remarkable triumph as MercuriX Racing is crowned the 2025 Singapore National STEM Racing Champions, an extraordinary achievement in only their second year participating, competing against 14 teams from 7 schools.
The team not only clinched the National Championship title but also secured wins as Knockout Racing Champions and the Best Video Presentation Award. Their outstanding performance has earned them the honour of representing Singapore at the 2026 World STEM Racing Championship, competing against the most accomplished young engineers across the globe.
What Is STEM Racing?
Supported by Formula 1®, STEM Racing, formerly known as F1 in Schools, is a prestigious international STEM competition for students aged 9 to 19 where participants design and manufacture miniature race cars using advanced CAD/CAM tools.
However, the competition extends far beyond engineering. Students innovate, collaborate, build brand associations, raise funds, and demonstrate prudent financial and time management, gaining practical competencies essential across professional industries.
The Team Driving Championship Success
Representing NLCS (Singapore), MercuriX Racing comprises six dedicated team members, Samuel (Team Manager), Braxton (Head of Engineering), Kerri (Manufacture Engineer), Yarun (Research Engineer), Evie (Head of Enterprise), and Denise (Head of Graphic Design). Each member brought their expertise to the table, creating a disciplined, communicative team united by a shared commitment to precision.
Head of Enterprise, Evie shared, "Seeing our identity come together across the portfolio, merchandise, social media, and pit display made all the long nights worth it. It made me feel like I helped shape how people saw us, and I am really proud of that.
Research Engineer, Yarun, added, "It taught us the importance of how a strong team isn't defined by job titles but by trust, collaboration and being there for each other."
Mastering Engineering Challenges with Innovation and Teamwork
This year's competition was among the most technically demanding, with many second-year teams competing for the National title and a place at the World Finals, but MercuriX Racing rose to the challenge. Using advanced tools such as Autodesk Fusion and ANSYS, the team simulated aerodynamics, refined structures, and evaluated performance variables before manufacturing began. Their final car was produced through a combination of CNC machining and 3D printing, resulting in a sleek, world-class design.
Manufacture Engineer, Kerri recalled that the team's biggest challenge was maintaining a high level of performance while still meeting strict regulations. However, they overcame this through an iterative engineering process of rapid prototyping, continuous simulation, and data-driven refinement.
"Through the multiple iterations of the car we had multiple 'eureka' moments that led to failure, but this experience taught us resilience and the value of further refining our ideas," Team Manager, Samuel added.
Crafting a Unique Team Identity
Beyond engineering excellence, the team delivered an impressive enterprise pitch and a cohesive brand identity grounded in their slogan, "Unleashing Speed and Engineering Excellence."
Denise, Head of Graphic Design shared, "MercuriX Racing is unique because of the team culture where everyone supported one another beyond their assigned roles, creating a team that was flexible, collaborative and deeply united. This identity helped us adapt quickly during the competition, solve problems faster, and stay confident when under pressure."
Insights from Mr Wilson Law on Building Success
For Wilson Law, Head of Design and Engineering at NLCS (Singapore), this year's success is the result of dedication and a strong culture of applied learning.
"STEM Racing reflects the kind of education we believe in at NLCS (Singapore), ambitious, academic, student-led, and grounded in real outcomes," he shared.
"Alongside my colleagues, our role was mainly to support and enable rather than direct, providing moral support, practical guidance at key moments, and the resources the team needed to execute well."
Looking Ahead to the International Stage
With their national win secured, MercuriX Racing now sets its sights on the STEM Racing World Finals 2026. Their goal is to refine their prototype, push boundaries, and represent NLCS (Singapore) with the same courage and excellence that brought them this victory.
Stay connected with MercuriX Racing on Instagram for more updates and to support them in this journey.
About North London Collegiate School (Singapore)
Founded in August 2020, North London Collegiate School (Singapore) is a British international school offering the academically ambitious NLCS curriculum, followed by the International Baccalaureate's Middle Years Programme and culminates in the IB Diploma Programme.
Drawing upon 175 years of educational heritage from its founding school in the UK, NLCS (Singapore) nurtures individuals to be intellectually curious, socially confident, and grounded in compassion. Every student is known, challenged, and celebrated through a rigorous academic framework, rich co-curricular opportunities, and exceptional pastoral care.
Situated on Depot Road, the school is part of a global family of schools committed to educational excellence and developing global citizens.
To learn more about NLCS (Singapore), please visit our website and follow us on Instagram, Facebook, YouTube and LinkedIn.
For media queries, please contact the NLCS (Singapore) Marketing Team
Email: marketing@nlcssingapore.sg
Or visit our website www.nlcssingapore.sg
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
MercuriX Racing Wins STEM Racing Nationals 2025, to Represent Singapore
|
In the news release, CooperVision Expands MyDay® MiSight® 1 day Myopia Control Soft Contact Lenses Into Asia Pacific Region, issued 02-Mar-2026 by CooperVision, Inc. over PR Newswire, we are advised by the company that changes have been made. The complete, corrected release follows, with additional details at the end:
CooperVision Expands MyDay® MiSight® 1 day Myopia Control Soft Contact Lenses Into Asia Pacific Region
Second Phase of Rollout Builds on Strong Momentum Across Europe and UK.
ROCHESTER, N.Y., March 2, 2026 /PRNewswire/ -- CooperVision is continuing its global rollout of MyDay® MiSight® 1 day contact lenses with immediate availability in Australia and New Zealand, marking the myopia control product's first entry into the Asia Pacific region. In addition, the innovative lenses are now shipping in South Africa, building on the initial launch earlier this year across Europe and the United Kingdom.
The expansions underscore the company's commitment to making evidence-based myopia management interventions accessible to eye care professionals (ECPs) and children worldwide.
"Myopia is a pressing health challenge of epic proportions, now affecting nearly one in three children worldwide," said Debbie Olive, Chief Commercial Officer for CooperVision.*1,2,3 "The growing availability and adoption of our myopia control contact lenses, including MyDay® MiSight® 1 day, are helping drive a meaningful shift in pediatric eye care by supporting children's vision today while helping protect their sight for the future."
MyDay® MiSight® 1 day combines the proven MiSight® 1 day ActivControl® Technology with the advanced silicone hydrogel material used in MyDay® lenses, offering "always-on" myopia control alongside the comfort and performance of a daily disposable silicone hydrogel lens.†4 This technology has demonstrated an approximate 50% reduction in myopia progression and is supported by the longest-running soft contact lens clinical trial for myopia control in children. ‡5,6
"The introduction of MyDay® MiSight® 1 day into the Asia Pacific region marks an important milestone in our global efforts to make the latest in evidence-based myopia control accessible to as many children as possible," said Jennifer Lambert, VP – Myopia Control & Cornea Care for CooperVision, CooperVision. "As MiSight® products become available in more markets worldwide, CooperVision's scale and focus are driving a shift in the paradigm, from simply correcting vision to actively controlling myopia progression."
CooperVision expects to continue its phased MyDay® MiSight® 1 day expansion in the coming months, including additional availability in Asia Pacific markets.
To find out more about CooperVision's contact lens portfolio and evidence-based myopia management interventions, visit: www.coopervision.com/select-region
About CooperVision
CooperVision, a division of CooperCompanies (Nasdaq: COO), is one of the world's leading manufacturers of contact lenses. The company produces a full array of daily disposable, two-week and monthly soft contact lenses that feature advanced materials and optics, and premium rigid gas permeable lenses for orthokeratology and scleral designs. CooperVision has a strong heritage of addressing the toughest vision challenges such as astigmatism, presbyopia, childhood myopia, and highly irregular corneas; and offers the most complete portfolio of spherical, toric and multifocal products available. Through a combination of innovative products and focused practitioner support, the company brings a refreshing perspective to the marketplace, creating real advantages for customers and wearers. For more information, visit www.coopervision.com.
About CooperCompanies
CooperCompanies (Nasdaq: COO) is a leading global medical device company focused on helping people experience life's beautiful moments through its two business units, CooperVision and CooperSurgical. CooperVision is a trusted leader in the contact lens industry, helping to improve the way people see each day. CooperSurgical is a leading fertility and women's healthcare company dedicated to putting time on the side of women, babies, and families at the healthcare moments that matter most. Headquartered in San Ramon, Calif., CooperCompanies has a workforce of more than 15,000, sells products in over 130 countries, and positively impacts over 50 million lives each year. For more information, please visit www.coopercos.com.
Forward-Looking Statements
This press release contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995 including, among others, statements regarding the launch of MyDay® MiSight® 1 day. Forward-looking statements necessarily depend on assumptions, data or methods that may be incorrect or imprecise and are subject to risks and uncertainties. Among the factors that could cause actual results and future actions to differ materially from those described in forward-looking statements are risks relating to challenges inherent in developing, manufacturing, launching, marketing, and selling new or alternative products; potential product performance, availability and quality issues; competition; launch delays; and other factors described in CooperCompanies' Securities and Exchange Commission filings, including the "Business", "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections in Cooper's Annual Report on Form 10-K for the fiscal year ended October 31, 2024, as such Risk Factors may be updated in annual and quarterly filings. CooperCompanies cautions investors that forward-looking statements reflect the company's analysis only on their stated date. CooperCompanies disclaims any intent to update them except as required by law.
Media Contact
Laura DiCaprio, APR
McDougall Communications for CooperVision
laura@mcdougallpr.com or +1-585-434-2148
_________________________________
* Based on a comprehensive analysis of 276 studies, involving a total of 5,410,945 children and adolescents with spherical equivalent of -0.50D or less, aged 6-19 from across 50 countries, with notable variations in prevalence across different demographic groups.
† Proven to slow myopia progression in children compared to a single vision 1-day lens over a 3-year period.
‡ Using measured and modeled data, pooled across ages (8-17), myopia progression was slowed by an average of approximately 50% with MiSight® 1 day, which shares the same ActivControl® Technology with MyDay® MiSight® 1 day.
_________________________________
1 Holden BA, Fricke TR, Wilson DA, et al. Global prevalence of myopia and high myopia and temporal trends from 2000 through 2050. Ophthalmology. 2016;123(5):1036-1042.
2 Liang J, Pu Y, Chen J, et al, Global prevalence, trend and projection of myopia in children and adolescents from 1990 to 2050: a comprehensive systematic review and meta-analysis, British Journal of Ophthalmology 2025;109:362-371.
3 James S. Wolffsohn, Monica Jong, Earl L. Smith, Serge R. Resnikoff, Jost B. Jonas, Nicola S. Logan, Ian Morgan, Padmaja Sankaridurg, Kyoko Ohno-Matsui; IMI 2021 Reports and Digest – Reflections on the Implications for Clinical Practice. Invest. Ophthalmol. Vis. Sci. 2021;62(5):1. https://doi.org/10.1167/iovs.62.5.1.
4 Chamberlain P et al A 3-year Randomized Clinical Trial of MiSight Lenses for Myopia Control. OVS 2019;96:556-567.
5 Arumugam B et al. Modelling Age Effects of Myopia Progression for the MiSight 1 day Clinical Trial. IOVS 2021;62(8):2333.
6 CVI data on file, 2025.
Photo - https://mma.prnasia.com/media2/2922809/CooperVision_MyDay_MiSight_1_day.jpg?p=medium600
Logo - https://mma.prnewswire.com/media/2854596/5829336/CooperVision_Logo.jpg
Correction: The first paragraph has been revised.
In the news release, CooperVision Expands MyDay® MiSight® 1 day Myopia Control Soft Contact Lenses Into Asia Pacific Region, issued 02-Mar-2026 by CooperVision, Inc. over PR Newswire, we are advised by the company that changes have been made. The complete, corrected release follows, with additional details at the end:
Second Phase of Rollout Builds on Strong Momentum Across Europe and UK.
ROCHESTER, N.Y., March 2, 2026 /PRNewswire/ -- CooperVision is continuing its global rollout of MyDay® MiSight® 1 day contact lenses with immediate availability in Australia and New Zealand, marking the myopia control product's first entry into the Asia Pacific region. In addition, the innovative lenses are now shipping in South Africa, building on the initial launch earlier this year across Europe and the United Kingdom.
The expansions underscore the company's commitment to making evidence-based myopia management interventions accessible to eye care professionals (ECPs) and children worldwide.
"Myopia is a pressing health challenge of epic proportions, now affecting nearly one in three children worldwide," said Debbie Olive, Chief Commercial Officer for CooperVision.*1,2,3 "The growing availability and adoption of our myopia control contact lenses, including MyDay® MiSight® 1 day, are helping drive a meaningful shift in pediatric eye care by supporting children's vision today while helping protect their sight for the future."
MyDay® MiSight® 1 day combines the proven MiSight® 1 day ActivControl® Technology with the advanced silicone hydrogel material used in MyDay® lenses, offering "always-on" myopia control alongside the comfort and performance of a daily disposable silicone hydrogel lens.†4 This technology has demonstrated an approximate 50% reduction in myopia progression and is supported by the longest-running soft contact lens clinical trial for myopia control in children. ‡5,6
"The introduction of MyDay® MiSight® 1 day into the Asia Pacific region marks an important milestone in our global efforts to make the latest in evidence-based myopia control accessible to as many children as possible," said Jennifer Lambert, VP – Myopia Control & Cornea Care for CooperVision, CooperVision. "As MiSight® products become available in more markets worldwide, CooperVision's scale and focus are driving a shift in the paradigm, from simply correcting vision to actively controlling myopia progression."
CooperVision expects to continue its phased MyDay® MiSight® 1 day expansion in the coming months, including additional availability in Asia Pacific markets.
To find out more about CooperVision's contact lens portfolio and evidence-based myopia management interventions, visit: www.coopervision.com/select-region
About CooperVision
CooperVision, a division of CooperCompanies (Nasdaq: COO), is one of the world's leading manufacturers of contact lenses. The company produces a full array of daily disposable, two-week and monthly soft contact lenses that feature advanced materials and optics, and premium rigid gas permeable lenses for orthokeratology and scleral designs. CooperVision has a strong heritage of addressing the toughest vision challenges such as astigmatism, presbyopia, childhood myopia, and highly irregular corneas; and offers the most complete portfolio of spherical, toric and multifocal products available. Through a combination of innovative products and focused practitioner support, the company brings a refreshing perspective to the marketplace, creating real advantages for customers and wearers. For more information, visit www.coopervision.com.
About CooperCompanies
CooperCompanies (Nasdaq: COO) is a leading global medical device company focused on helping people experience life's beautiful moments through its two business units, CooperVision and CooperSurgical. CooperVision is a trusted leader in the contact lens industry, helping to improve the way people see each day. CooperSurgical is a leading fertility and women's healthcare company dedicated to putting time on the side of women, babies, and families at the healthcare moments that matter most. Headquartered in San Ramon, Calif., CooperCompanies has a workforce of more than 15,000, sells products in over 130 countries, and positively impacts over 50 million lives each year. For more information, please visit www.coopercos.com.
Forward-Looking Statements
This press release contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995 including, among others, statements regarding the launch of MyDay® MiSight® 1 day. Forward-looking statements necessarily depend on assumptions, data or methods that may be incorrect or imprecise and are subject to risks and uncertainties. Among the factors that could cause actual results and future actions to differ materially from those described in forward-looking statements are risks relating to challenges inherent in developing, manufacturing, launching, marketing, and selling new or alternative products; potential product performance, availability and quality issues; competition; launch delays; and other factors described in CooperCompanies' Securities and Exchange Commission filings, including the "Business", "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections in Cooper's Annual Report on Form 10-K for the fiscal year ended October 31, 2024, as such Risk Factors may be updated in annual and quarterly filings. CooperCompanies cautions investors that forward-looking statements reflect the company's analysis only on their stated date. CooperCompanies disclaims any intent to update them except as required by law.
Media Contact
Laura DiCaprio, APR
McDougall Communications for CooperVision
laura@mcdougallpr.com or +1-585-434-2148
_________________________________
* Based on a comprehensive analysis of 276 studies, involving a total of 5,410,945 children and adolescents with spherical equivalent of -0.50D or less, aged 6-19 from across 50 countries, with notable variations in prevalence across different demographic groups.
† Proven to slow myopia progression in children compared to a single vision 1-day lens over a 3-year period.
‡ Using measured and modeled data, pooled across ages (8-17), myopia progression was slowed by an average of approximately 50% with MiSight® 1 day, which shares the same ActivControl® Technology with MyDay® MiSight® 1 day.
_________________________________
1 Holden BA, Fricke TR, Wilson DA, et al. Global prevalence of myopia and high myopia and temporal trends from 2000 through 2050. Ophthalmology. 2016;123(5):1036-1042.
2 Liang J, Pu Y, Chen J, et al, Global prevalence, trend and projection of myopia in children and adolescents from 1990 to 2050: a comprehensive systematic review and meta-analysis, British Journal of Ophthalmology 2025;109:362-371.
3 James S. Wolffsohn, Monica Jong, Earl L. Smith, Serge R. Resnikoff, Jost B. Jonas, Nicola S. Logan, Ian Morgan, Padmaja Sankaridurg, Kyoko Ohno-Matsui; IMI 2021 Reports and Digest – Reflections on the Implications for Clinical Practice. Invest. Ophthalmol. Vis. Sci. 2021;62(5):1. https://doi.org/10.1167/iovs.62.5.1.
4 Chamberlain P et al A 3-year Randomized Clinical Trial of MiSight Lenses for Myopia Control. OVS 2019;96:556-567.
5 Arumugam B et al. Modelling Age Effects of Myopia Progression for the MiSight 1 day Clinical Trial. IOVS 2021;62(8):2333.
6 CVI data on file, 2025.
Photo - https://mma.prnasia.com/media2/2922809/CooperVision_MyDay_MiSight_1_day.jpg?p=medium600
Logo - https://mma.prnewswire.com/media/2854596/5829336/CooperVision_Logo.jpg
Correction: The first paragraph has been revised.
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
CooperVision Expands MyDay® MiSight® 1 day Myopia Control Soft Contact Lenses Into Asia Pacific Region
